title: Cutaneous manifestations of connective tissue disease.
abstract: There is evidence that early treatment of connective tissue in adolescence improves clinical outcomes; thus, recognition of the cutaneous manifestation of CTD is critical. This review summarizes the clinical features that are unique to children and adolescents in cutaneous (CLE) and systemic lupus erythematosus (SLE), juvenile dermatomyositis (JDM), juvenile systemic scleroderma (JSS), juvenile localized scleroderma (JLS), and juvenile inflammatory arthritis (JIA).
authors.affiliation: Indiana University School of Medicine, Indianapolis, IN, USA.
authors.forename: Erin
authors.initials: E
authors.lastname: McCammack
authors.forename: Anita N
authors.initials: AN
authors.lastname: Haggstrom
mesh_terms: D000293:Adolescent; D018501:Antirheumatic Agents / Q000627:therapeutic use; D003240:Connective Tissue Diseases / Q000188:drug therapy* / Q000503:physiopathology*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy / Q000503:physiopathology; D008179:Lupus Erythematosus, Discoid / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D018501:Antirheumatic Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D006886:Hydroxychloroquine